Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: Marshall001 who wrote (96028)	4/13/2000 10:22:00 AM
From: marquis103	Respond to of 108040

SCLN. Russ Thursday April 13, 9:30 am Eastern Time Company Press Release SOURCE: SciClone Pharmaceuticals SciClone's ZADAXIN(R) Approved in South Korea SAN MATEO, Calif., April 13 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN - news) today announced the approval of ZADAXIN, its lead immunotherapy, in South Korea, one of the world's largest pharmaceutical markets. The South Korean approval is for use of ZADAXIN as an influenza vaccine adjuvant by individuals with weakened immune systems. Similar to ZADAXIN approvals in Argentina and Mexico, this approval is expected to be expanded to include use for treatment of hepatitis B and hepatitis C. ``South Korea is the 20th international market which has approved ZADAXIN for public sale,' said Donald R. Sellers, SciClone's President and CEO. ``In terms of continuing our targeted 100 percent annual revenue growth, this is one of our most important developments since the initial ZADAXIN approval in China. We plan the commercial launch of ZADAXIN in South Korea later this year, following the upcoming launches in Italy and Mexico.' ZADAXIN enhances the activity of the host immune system. ZADAXIN co-administration with the influenza vaccine primes the immune system to respond to the vaccine thereby conferring immunity. ZADAXIN immunotherapy has now been approved for use in 20 countries and marketing applications are pending in 17 additional countries. The drug has been approved principally as a treatment for hepatitis B and hepatitis C. In addition, it is becoming a key component in multiple drug treatments for several types of cancer, infectious diseases and immune system disorders. In Japan, SciClone's partner, Schering-Plough K.K, is undertaking Phase 3 hepatitis B and Phase 2 hepatitis C trials for ZADAXIN. SciClone plans to commence late-stage ZADAXIN clinical programs in hepatitis C, hepatitis B, malignant melanoma and liver cancer in the U.S. this year, as well as a complementary pivotal phase 3 hepatitis C program in Europe with partner Sigma-Tau. SciClone Pharmaceuticals is a global specialty pharmaceutical company that develops and commercializes novel medicines for the treatment of a broad range of the world's most serious diseases. The Company is currently targeting cancer, hepatitis B, hepatitis C, drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at www.sciclone.com or by calling the Company's Investor Relations Department at 800-724-2566. SciClone's Common Stock is listed on The Nasdaq National Market© under the symbol SCLN. The information in this press release includes certain forward-looking statements concerning the Company's current expectations regarding future events. This includes, the ongoing and prospective development and commercialization of ZADAXIN immunotherapy for cancer, infectious diseases and immune system disorders, the continued growth in ZADAXIN sales and the timelines of ZADAXIN launches in Mexico, Italy and South Korea. Due to market factors and the nature of product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission, particularly its Annual Report on Form 10-K for the year ended December 31, 1999.